Navigation Links
Development of a therapeutic algorithm for optimal nosebleed management
Date:8/26/2013

Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of OtolaryngologyHead and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.

"Although data exist on the efficacy of the different epistaxis management techniques, outcome comparisons between the modalities for both primary management as well as management of cases of recurrence are currently lacking," the authors stated.

The study analyzed various treatment outcomes of adult patients with epistaxis presenting to otolaryngologists at a tertiary care center between 2005 and 2011. The authors observed 147 patients (94 men and 53 women) who underwent cauterization, tamponade or nondissolvable packing, and/or proximal vascular control through embolization or surgical ligation. Treatment outcomes were then compared with the intent to derive an algorithm for optimal nosebleed management.

According to the study, nondissolvable packing demonstrated the highest rate of failure or recurrence (57.4 percent) for initial bleed management. Chemical cautery was significantly more successful in achieving lasting hemostasis for the first bleeding episode. The authors also found that the duration of the nondissolvable pack placement had no significant impact on nosebleed recurrence. Furthermore, among patients who failed initial management, those who next underwent more invasive procedures such as cautery, embolization or surgical ligation experienced better outcomes and shorter inpatient stays.

Because the subgroup analyses were limited in size for some of the treatment groups in this study, the authors urge caution when considering these findings.

Although most cases of nosebleed do not require medical intervention, those patients who do present to a tertiary care otolaryngologist and need medical attention require a systematic, stepwise approach to address their condition. This study demonstrates "good outcomes with initial treatment with chemical cautery and with procedures that achieve directed vascular control in patients who develop epistaxis recurrence."


'/>"/>

Contact: Lindsey Walter
newsroom@entnet.org
703-535-3762
American Academy of Otolaryngology - Head and Neck Surgery
Source:Eurekalert

Related medicine news :

1. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
2. Kudos for 3 NJIT Enterprise Development Center high-tech companies
3. 2 repressor genes identified as essential for placental development
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Advanced genetic screening method may speed vaccine development
6. New biospecimens management system in development
7. Developmental Woes Common in Siblings of Children With Autism
8. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
9. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
10. Study sheds new light on role of genetic mutations in colon cancer development
11. The first day of development -- a window to successful pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... ... 20, 2017 , ... Doctor C LLC, a company based out of Arizona ... to continue the marketing and distribution of its product, The Right C. , The ... better absorption than traditional vitamin C supplements. At the trade show, Doctor C had ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, Inc., ... data on the Company,s lead investigational immuno-oncology drug AM0010 ... by the American Society of Clinical Oncology (ASCO), taking ... CA. "AM0010 induces the ... + T cells in the blood and tumors ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c ... End-use, And Segment Forecasts, 2013 - 2024" report to their ... The ... billion by 2024 Introduction of innovative solutions on the ...
Breaking Medicine Technology: